Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis

Transplantation

Volumn 101, Issue 8, 2017, Pages 1867-1874

  Bhati, Chandra ^a   Idowu, Michael O ^a   Sanyal, Arun J ^a   Rivera, Maria ^a   Driscoll, Carolyn ^a   Stravitz, Richard T ^a   Kohli, Divyanshoo R ^a   Matherly, Scott ^a   Puri, Puneet ^a   Gilles, HoChong ^b   Cotterell, Adrian ^a   Levy, Marlon ^a   Sterling, Richard K ^a   Luketic, Velimir A ^a   Lee, Hannah ^a   Sharma, Amit ^a   Siddiqui, Mohammad Shadab ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PORTAL HYPERTENSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TRANSIENT ELASTOGRAPHY; TREATMENT OUTCOME; BIOPSY; COMPLICATION; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES; TIME FACTOR;

BIOPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85015240817     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001709     Document Type: Article

References (45)

1. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence ofthe most common causes of chronic liver diseases in the united statesfrom 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524. e1-530. e1;quiz e60.
2. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulinresistance, metabolic syndrome: Further evidence for an etiologic association. Hepatology. 2002;35:367-372.
3. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory andhistological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52:913-924.
4. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histologicalscoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
5. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepaticsteatosis in an urban population in the united states: Impact of ethnicity. Hepatology. 2004;40:1387-1395.
6. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is thesecond leading etiology of liver disease among adults awaiting liver transplantationin the united states. Gastroenterology. 2015;148:547-555.
7. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes ofliver transplantation for nonalcoholic steatohepatitis in the united states. Gastroenterology. 2011;141:1249-1253.
8. Siddiqui MS, Charlton M. Liver transplantation for alcoholic and nonalcoholicfatty liver disease: Pretransplant selection and posttransplant management. Gastroenterology. 2016;150:1849-1862.
9. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fattyliver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001;7:363-373.
10. Yalamanchili K, Saadeh S, Klintmalm GB, et al. Nonalcoholic fatty liver diseaseafter liver transplantation for cryptogenic cirrhosis or nonalcoholicfatty liver disease. Liver Transpl. 2010;16:431-439.
11. Hejlova I, Honsova E, Sticova E, et al. Prevalence and risk factors ofsteatosis after liver transplantation and patient outcomes. Liver Transpl. 2016;22:644-655.
12. Seo S, Maganti K, Khehra M, et al. De novo nonalcoholic fatty liver diseaseafter liver transplantation. Liver Transpl. 2007;13:844-847.
13. Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver diseasein liver transplant recipients: Another story of "seed and soil". Am JGastroenterol. 2010;105:613-620.
14. Vallin M, Guillaud O, Boillot O, et al. Recurrent or de novo nonalcoholicfatty liver disease after liver transplantation: Natural history based on liverbiopsy analysis. Liver Transpl. 2014;20:1064-1071.
15. Watt KD, Pedersen RA, Kremers WK, et al. Evolution of causes and riskfactors for mortality post-liver transplant: Results of the NIDDK long-termfollow-up study. Am J Transplant. 2010;10:1420-1427.
16. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement:a 5-year prospective study of 13, 369 examinations. Hepatology. 2010;51:828-835.
17. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter(CAP): A novel VCTE™ guided ultrasonic attenuation measurementfor the evaluation of hepatic steatosis: Preliminary study andvalidation in a cohort of patients with chronic liver disease from variouscauses. Ultrasound Med Biol. 2010;36:1825-1835.
18. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging moreaccurately classifies steatosis and fibrosis in patients with nonalcoholicfatty liver disease than transient elastography. Gastroenterology. 2016;150:626. e7-637. e7.
19. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am JGastroenterol. 2012;107:1862-1871.
20. de Lédinghen V, Wong GL, Vergniol J, et al. Controlled attenuation parameterfor the diagnosis of steatosis in non-alcoholic fatty liver disease. JGastroenterol Hepatol. 2016;31:848-855.
21. de Lédinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter(CAP) for the diagnosis of steatosis: A prospective study of 5323examinations. J Hepatol. 2014;60:1026-1031.
22. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosisusing liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454-462.
23. de Lédinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis andcirrhosis using liver stiffness measurement: Comparison between M and XL probe of Fibro Scan® . J Hepatol. 2012;56:833-839.
24. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologicfeatures, is associated with long-term outcomes of patients with nonalcoholicfatty liver disease. Gastroenterology. 2015;149:389-397. e10.
25. Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognosticsignificance of blood fibrosis tests and liver stiffness measurementby Fibro Scan in non-alcoholic fatty liver disease. J Hepatol. 2016;65:570-578.
26. Lutz HH, Schroeter B, Kroy DC, et al. Doppler ultrasound and transientelastography in liver transplant patients for noninvasive evaluation of liverfibrosis in comparison with histology: A prospective observational study. Dig Dis Sci. 2015;60:2825-2831.
27. Crespo G, Lens S, Gambato M, et al. Liver stiffness 1 year after transplantationpredicts clinical outcomes in patients with recurrent hepatitis C. Am J Transplant. 2014;14:375-383.
28. Barrault C, Roudot-Thoraval F, Tran Van Nhieu J, et al. Non-invasive assessmentof liver graft fibrosis by transient elastography after liver transplantation. Clin Res Hepatol Gastroenterol. 2013;37:347-352.
29. Rigamonti C, Fraquelli M, Bastiampillai AJ, et al. Transient elastographyidentifies liver recipients with nonviral graft disease after transplantation:a guide for liver biopsy. Liver Transpl. 2012;18:566-576.
30. Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis:Non-invasive assessment of non-alcoholic fatty liver disease-the role oftransient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269.
31. Noureddin M, Yates KP, Vaughn IA, et al. Clinical and histological determinantsof nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58:1644-1654.
32. Siddiqui MS, Cheang KL, Luketic VA, et al. Nonalcoholic steatohepatitis(NASH) is associated with a decline in pancreatic beta cell (-cell) function. Dig Dis Sci. 2015;60:2529-2537.
33. Siddiqui MS, Fuchs M, Idowu MO, et al. Severity of nonalcoholic fatty liverdisease and progression to cirrhosis are associated with atherogenic lipoproteinprofile. Clin Gastroenterol Hepatol. 2015;13:1000-8. e3.
34. Castera L. Noninvasive evaluation of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:291-303.
35. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transientelastography for the diagnosis of fibrosis in pediatric nonalcoholicsteatohepatitis. Hepatology. 2008;48:442-448.
36. Lupsor M, Badea R, Stefanescu H, et al. Performance of unidimensionaltransient elastography in staging non-alcoholic steatohepatitis. JGastrointestin Liver Dis. 2010;19:53-60.
37. Petta S, Di Marco V, Cammà C, et al. Reliability of liver stiffness measurementin non-alcoholic fatty liver disease: The effects of body mass index. Aliment Pharmacol Ther. 2011;33:1350-1360.
38. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnosticperformance of the Fibro Scan XL probe for liver stiffness measurement inoverweight and obese patients. Hepatology. 2012;55:199-208.
39. Siddiqui MS, Sterling RK. Posttransplant metabolic syndrome. Int JHepatol. 2012;2012:891516.
40. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fattyliver vs nonalcoholic steatohepatitis: A systematic review and metaanalysisof paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643-654. e1-9; quiz e39-40.
41. Chhatrala R, Siddiqui MB, Stravitz RT, et al. Evolution of serum atherogenicrisk in liver transplant recipients: Role of lipoproteins and metabolicand inflammatory markers. Liver Transpl. 2015;21:623-630.
42. Idowu MO, Chhatrala R, Siddiqui MB, et al. De novo hepatic steatosisdrives atherogenic risk in liver transplantation recipients. Liver Transpl. 2015;21:1395-1402.
43. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patientsundergoing orthotopic liver transplantation in the United States. Hepatology. 2002;35:105-109.
44. Singhal A, Wilson GC, Wima K, et al. Impact of recipientmorbid obesity onoutcomes after liver transplantation. Transpl Int. 2015;28:148-155.
45. Perez-Protto SE, Quintini C, Reynolds LF, et al. Comparable graft and patientsurvival in lean and obese liver transplant recipients. Liver Transpl. 2013;19:907-915.